Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care
Mené en Allemagne sur 1 229 patientes atteintes d'un cancer invasif du sein, cet essai randomisé de phase III compare l'efficacité, du point de vue de la réponse pathologique complète, et la toxicité du nab-paclitaxel par rapport au paclitaxel en solution avant un traitement néoadjuvant à base d'épirubicine et de cyclophosphamide
The value of clinical trials in the neoadjuvant setting has been overwhelmingly demonstrated in the past few decades. Neoadjuvant trials focus on intermediate endpoints (eg, pathological complete response [pCR]) that have been shown to correlate with the ultimate endpoints of event-free and overall survival. The link between the achievement of pCR and the long-term clinical benefit was supported by findings of a pooled analysis, with the greatest prognostic value observed in aggressive tumour subtypes.
The Lancet Oncology , commentaire, 2015